Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer

Author:

Vasista Anuradha1,Stockler Martin1,Martin Andrew1,Pavlakis Nick2,Sjoquist Katrin13,Goldstein David4,Gill Sanjeev5,Jain Vikram6,Liu Geoffrey7,Kannourakis George8,Kim Yeul Hong9,Nott Louise10,Snow Stephanie11,Burge Matthew12,Harris Dean13,Jonker Derek14,Chua Yu Jo15,Epstein Richard16,Bonaventura Antony17,Kiely Belinda1

Affiliation:

1. NHMRC Clinical Trials Centre, University of Sydney, New South Wales, Australia

2. Royal North Shore Hospital, New South Wales, Australia

3. St George Hospital, New South Wales, Australia

4. Prince of Wales Hospital, New South Wales, Australia

5. The Alfred Hospital, Victoria, Australia

6. ICON Cancer Foundation, Queensland, Australia

7. University Health Network, Princess Margaret Hospital, Toronto, Canada

8. Ballarat Oncology and Haematology Services, Ballarat, Victoria, Australia

9. Korea University Hospital, South Korea

10. Royal Hobart Hospital, Tasmania, Australia

11. Queen Elizabeth II Health Sciences Centre, Nova Scotia, Canada

12. Royal Brisbane and Womens Hospital, Queensland, Australia

13. Christchurch Hospital, Canterbury, New Zealand

14. Ottawa Health Research Institute, Ottawa, Canada

15. Canberra Hospital, Australian Capital Territory, Australia

16. The Kinghorn Cancer Centre, St Vincent's Hospital, New South Wales, Australia

17. Newcastle Private Hospital, New South Wales, Australia

Abstract

Abstract Background Worst-case, typical, and best-case scenarios for survival, based on simple multiples of an individual's expected survival time (EST), estimated by their oncologist, are a useful way of formulating and explaining prognosis. We aimed to determine the accuracy and prognostic significance of oncologists’ estimates of EST, and the accuracy of the resulting scenarios for survival time, in advanced gastric cancer. Materials and Methods Sixty-six oncologists estimated the EST at baseline for each of the 152 participants they enrolled in the INTEGRATE trial. We hypothesized that oncologists’ estimates of EST would be unbiased (∼50% would be longer or shorter than the observed survival time [OST]); imprecise (<33% within 0.67–1.33 times the OST); independently predictive of overall survival (OS); and accurate at deriving scenarios for survival time with approximately 10% of patients dying within a quarter of their EST (worst-case scenario), 50% living within half to double their EST (typical scenario), and 10% living three or more times their EST (best-case scenario). Results Oncologists’ estimates of EST were unbiased (45% were shorter than the OST, 55% were longer); imprecise (29% were within 0.67–1.33 times observed); moderately discriminative (Harrell's C-statistic 0.62, p = .001); and an independently significant predictor of OS (hazard ratio, 0.89; 95% confidence interval, 0.83–0.95; p = .001) in a Cox model including performance status, number of metastatic sites, neutrophil-to-lymphocyte ratio ≥3, treatment group, age, and health-related quality of life (EORTC-QLQC30 physical function score). Scenarios for survival time derived from oncologists’ estimates were remarkably accurate: 9% of patients died within a quarter of their EST, 57% lived within half to double their EST, and 12% lived three times their EST or longer. Conclusion Oncologists’ estimates of EST were unbiased, imprecise, moderately discriminative, and independently significant predictors of OS. Simple multiples of the EST accurately estimated worst-case, typical, and best-case scenarios for survival time in advanced gastric cancer. Implications for Practice Results of this study demonstrate that oncologists’ estimates of expected survival time for their patients with advanced gastric cancer were unbiased, imprecise, moderately discriminative, and independently significant predictors of overall survival. Simple multiples of the expected survival time accurately estimated worst-case, typical, and best-case scenarios for survival time in advanced gastric cancer.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference15 articles.

1. Chemotherapy for advanced gastric cancer;Wagner;Cochrane Database Syst Rev,2017

2. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity;Yang;J Gastrointest Oncol,2011

3. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy;Bernards;Ann Oncol,2013

4. Using scenarios to explain life expectancy in advanced cancer: Attitudes of people with a cancer experience;Kiely;Support Care Cancer,2013

5. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: A systematic review of recent randomized trials;Kiely;J Clin Oncol,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3